European Society of Contraception
|
|
|
APRIL 30 – MAY 3 2008 PRAGUE, CZECH REPUBLIC |
|
SCIENTIFIC PROGRAMME |
|||
|
|
|||
| Keynote lectures | Plenary sessions | Congress sessions (state of the art) | Fora |
| Workshops | Meet the expert sessions | Working groups sessions | Society sessions |
| Symposia | Free communication sessions | Young scientist session Posters | CME
credits |
|
|
|||
|
Congress sessions (state of the art): in each of these 6 sessions, three or four experts will provide up to date information on a topic, with plenty of opportunity for questions. There will be two selected free communications added to each session. |
|||
|
|
|||
Critical evaluation and clinical management of side effects
| Screening and management of STI in family planning
| Do guidelines make any change? (WHO special session)
| Induced abortion – An update
| Contraception for medically compromised women
| Critical evaluation and clinical management of side effects | |
|
Chair: D. Cibula (Czech Rep) • K. Sedlecki (Serbia) |
|
|
• |
Mood
changes/depression, R. Van Lunsen (The Netherlands) |
|
• |
Weight
changes, M. Lech (Poland) |
|
• |
BMD, D. Cibula (Czech Rep.) |
|
• |
Breakthrough bleeding, D. Archer (USA) |
|
|
|
| Screening and management of STI
in family planning |
|
| Chair: V. Cupanik (Slovakia) • T. Bombas
(Portugal) |
|
|
• |
WHO Global STI Epidemiology Update , G. Lazdane (WHO,
Copenhagen) |
|
• |
Testing for STIs in a Family Planning Setting – How
to Make It Simple?, A. Bigrigg (United Kingdom) |
|
• |
Guidelines for HPV
DNA Testing – To Test or not to Test, Speaker TBC |
|
• |
Genital
Chlamydial Infection: Has the Risk for Tubal Factor Infertility and Adverse Pregnancy Outcome been Exaggerated? Speaker TBC |
|
|
|
| Intrauterine
contraception |
|
| Chair: G. Bartfai (Hungary) • C. McNicholas (Ireland) | |
|
• |
IUD/IUS in nulliparous women, I. Sivin (USA) |
|
• |
Management in
special clinical conditions (dysplasia, postpartum insertion, HIV, emergency contraception …), D. Serfaty (France) |
|
• |
Non-contraceptive benefits, D. Mansour (United Kingdom) |
|
• |
Long-term
use/use beyond recommended time, I. Batar (Hungary) |
|
|
|
| Do guidelines make
any change? (WHO special session) |
|
| Chair: V. Cupanik (Slovakia) • I.
Savelieva (Russia) |
|
|
• |
The WHO family planning cornerstones: a living
testimony to the power of partnership, P. van Look (WHO, Geneva) |
|
• |
Implementation of family planning guidelines in Europe – adoption and adaptation, G. Lazdane (WHO, Copenhagen) |
|
• |
Recommended changes
in practice, A. Glasier (United Kingdom) |
|
|
|
| Induced abortion – An update | |
|
Chair: V. Prilepskaya (Russia) • A. Pretnar-Darovec (Slovenia) |
|
|
• |
The challenge of post-abortion contraception, K. Gemzell (Sweden) |
|
• |
Follow-up after induced abortion: current practice and evidence, C. Fiala (Austria) |
|
• |
Access to safe abortion: legal and other
obstacles, M. Vekemans (United Kingdom) |
|
|
|
| Contraception for medically
compromised women |
|
| Chair: S. Özalp (Turkey) • H. Missey-Kolb
(France) |
|
|
• |
|
Hormonal Contraception in women with disorders of
carbohydrate metabolism, A. Cagnacci (Italy)
•
Hormonal
contraception in women with coagulation disorders and thrombophilia,
J. Connard (France)
•
Hormonal Contraception in Women with Mental
Diseases, T. Backstrom (Sweden)
•
Contraceptive Management of women
or couples with HIV, S. Killick (United Kingdom)
